Loading stock data…
REPL
$2.50-0.07 (-2.72%)
Market ClosedLast close May 1
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Replimune Group, Inc. in the Healthcare sector is trading at $2.50. The stock is currently near its 52-week low of $1.50, remaining 64.0% below its 200-day moving average. Technical signals show neutral RSI of 62 and bullish MACD crossover, explaining why REPL maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 62) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.50
Potential Upside
5%
Whystock Fair Value$2.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intend...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$187.44M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-133.10%
Volume
Today's trading volume
3.44M
Recent News
Jefferies Sees Reduced Visibility for Replimune Group, Inc. (REPL) Following FDA Decision
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Replimune Group, Inc. is among the best biotech stocks to invest in. TheFly reported on April 13 that Jefferies cut its rating on REPL from Buy to Hold and reduced its price target sharply to $2 from $13. The firm […]
Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns
In April 2026, Replimune Group received a complete response letter from the FDA for its BLA seeking approval of RP1 plus nivolumab for advanced melanoma, despite earlier breakthrough therapy designation and priority review. The company contends that the FDA’s shifting review teams and changing interpretations of trial design and data adequacy undermined a previously agreed regulatory pathway for RP1. Next, we’ll explore how the FDA’s complete response letter and concerns over trial design...
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.2% and the State
Top Midday Decliners
Replimune (REPL) is facing "significant risk" related to its ongoing phase 3 trial of RP1 in melanom
Replimune Plans Layoffs After FDA Rejects Cancer Therapy. The Stock Hits an All-Time Low.
Shares of Replimune Group receive multiple downgrades after the Food and Drug Administration twice rejects its experimental cancer drug.